12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
each of multiple PNH subpopulations (Table 1) including patients with:
(1) a history of bone marrow dysfunction (AA or MDS); (2) thrombocytopenia;
(3) lower levels of reticulocytes; (4) different concomitant medications
including steroids or erythropoietin; (5) smaller proportions of
PNH cells (PNH clone size); (6) lower levels of baseline hemolysis; (7)
lower levels of anemia; (8) minimal pre-treatment transfusion requirements;
(9) and without complete transfusion independence during
eculizumab treatment. Significant improvements in hemolysis (p